Request an Annual Quote
The study will analyze blood samples of up to 96 patients using Illumina's TruSight Oncology 500 circulating tumor DNA comprehensive genomic profiling assay.
The firm intends to simplify the design and execution of deep cell profiling, and standardize sample analysis with reproducible workflows and automation.
The French bioinformatics firm will look to grow internationally and develop new tools to address cancer and hereditary diseases.
When patients with a specific biomarker are identified via NeoGenomics' tests, they will be connected with support groups and resources.
Last week, GenomeWeb's readers were most interested in Sema4's planned acquisition of genetic testing company GeneDx.
Combining eQTL and GWAS results, researchers at the Icahn School of Medicine at Mount Sinai detected hundreds of candidate causal variants for various brain traits.
News items for the week of Jan. 17, 2022.
The project will use genomic and other health data from All of Us Research Program participants to study factors that can inform personalized nutrition recommendations.